Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus COR OTICIN.
CARMOL HC vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic